Letaplimab represents a unique clinical method for addressing complement-mediated diseases. This antibody targets C1q, a essential factor of the complement cascade, aiming to inhibit its early triggering. Early https://oisitrow846036.blogdigy.com/letaplimab-a-new-medical-method-65287580